Answers are grounded in this paper and cite their sources.
Glioblastoma (GB) is the most aggressive form of malignant glioma, characterized by a low survival rate and minimal improvements in patient outcomes over the past three decades. This study investigates the feasibility of detecting circulating cell-free DNA (cfDNA) and analyses its dynamic fluctuations in a cohort of 59 patients undergoing chemoradiation treatment according to the standardized “Stupp protocol”. In our cohort, longitudinal cfDNA levels remained broadly stable at the population level over the follow-up period; however, substantial inter-individual variability in individual trajectories was observed, highlighting the complexity of cfDNA dynamics in GB. At the individual level, longitudinal monitoring revealed that cfDNA levels generally declined following surgery and chemoradiotherapy, yet increased prior to or coinciding with radiological progression, supporting its potential utility as a biomarker for tumour burden estimation and treatment response monitoring. We further developed a cfDNA index model correlating preoperative cfDNA levels with gross tumour volume and clinical target volume, demonstrating a statistically significant association with radiological progression. To the best of our knowledge, this is the first study to propose a mathematically derived cfDNA index in GB. This simple, low-cost, and minimally invasive approach may offer a valuable tool for early risk stratification at diagnosis, complement longitudinal clinical assessment, and support individualized treatment planning and surveillance. Overall, these findings reinforce the potential of cfDNA quantification as an accessible biomarker to advance precision medicine in GB.
No takes yet. Share an insight, caveat, or question.
Roda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: